Industry News
Biotechnology Industry News

GSK has walked away from a $2.2…
GSK has walked away from a $2.2 billion biobucks neurodegenerative disease pact with Alector that has seen both “next generation” drugs involved flunk clinical trials.
For a biotech, your intellectual…
For a biotech, your intellectual property is your most prized asset. But a new era of increased global competition means that strong patents, longer stealth periods and even some misdirection can be required to ensure
The FDA has paused a controversial…
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has learned, following a citizen’s petition from an unnamed pharma company in April.
Insurance coverage losses caused…
Insurance coverage losses caused by the Trump administration's tax and spend law could make it harder for biotechs to secure funding and recruit patients for trials, experts have told Fierce.
Prime Medicine has come out ahead…
Prime Medicine has come out ahead in its patent dispute with fellow gene-editing biotech Beam Therapeutics, after a panel of adjudicators ruled that the company did not violate its agreement with Beam and can continue
Satellos Bioscience has shared…
Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy drug candidate is active in adults, leading analysts to predict the molecule “could re-imagine the ... therapeutic landscape” if the biotech replicates the data in
Precision immunology company…
Precision immunology company Scipher Medicine will absorb Chemomab Therapeutics after having identified the Israeli biotech’s liver disease drug as the ideal fit for its own expertise.
AstraZeneca is paying Sino…
AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & Co.’s chronic obstructive pulmonary disease drug Ohtuvayre.
As MeiraGTx lines up the pieces…
As MeiraGTx lines up the pieces for a commercial push, the company has new funding to work with.
Biocytogen and Whitehawk…
Biocytogen and Whitehawk Therapeutics are joining forces to develop bispecific antibody-drug conjugates using Biocytogen's discovery platform.
Clinical-stage Kalohexis is…
Clinical-stage Kalohexis is readying a public listing to support its obesity and cancer cachexia treatments.
Boehringer Ingelheim has landed an…
Boehringer Ingelheim has landed an exclusive license to Prime Vector Technologies’ viral vector platform for developing next-generation cancer vaccines.
Phase 3 trials of Kailera…
Phase 3 trials of Kailera Therapeutics’ oral GLP-1 prospect have hit their primary endpoints, positioning the biotech’s partner Hengrui Pharma to seek approval in obesity and diabetes in China.
As U.S. lawmakers continue to…
As U.S. lawmakers continue to scrutinize the consequences of China’s expanding role in biotech innovation, industry insiders have been left debating how they can navigate this shifting landscape—or even whether biotechs should abandon China altogether.
Novartis is pushing deeper into…
Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload.
A month after Genentech confirmed…
A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed that this has formed part of a round of 103 layoffs.
Scribe Therapeutics is the latest…
Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials.
United Therapeutics has paid $140…
United Therapeutics has paid $140 million to buy Thymmune Therapeutics for preclinical regenerative cell therapies focused on the thymus.
AstraZeneca has added another…
AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug candidates.
A Fosun Pharma subsidiary has paid…
A Fosun Pharma subsidiary has paid Junshi Biosciences 215 million yuan ($32 million) for Chinese rights to a near-approval autoimmune disease drug candidate.

